Advanced Risk Stratification: Genomic Testing

While your pathology report describes what the cancer looks like, genomic testing (also called molecular profiling or gene expression assays) looks at what the cancer is doing. These tests analyze the RNA or expression signatures of specific genes within the tumor to predict how likely the cancer is to return and, most importantly, whether chemotherapy will actually help prevent that recurrence ^[1][2].

It is important to distinguish these from “genetic tests” (like BRCA1/2 testing). Germline genetic testing looks at the inherited DNA you were born with to see if you have a family risk of cancer, which can impact your surgical choices and relatives. Genomic tests look only at the expression signatures of the tumor itself to guide your specific systemic treatment plan.

The Recurrence Score: Oncotype DX

The most common genomic test for ER-positive, HER2-negative breast cancer is Oncotype DX. It looks at 21 different genes to produce a Recurrence Score (RS) from 0 to 100 ^[1].

A lower score generally means the cancer is less aggressive and hormone therapy alone may be enough. A higher score suggests the cancer is more likely to return and that chemotherapy may significantly lower that risk ^[2]. However, the “cutoff” for what is considered a high or low score changes depending on your age and whether you have gone through menopause.

For Women Over Age 50 (Postmenopausal)

In postmenopausal women, data from the TAILORx (node-negative) and RxPONDER (1-3 positive nodes) trials give clear guidance ^[3][4]:

• Score 0–25: There is typically no meaningful average added benefit from chemotherapy ^[5][4]. This is true for both node-negative disease and for patients with 1 to 3 positive lymph nodes ^[4]. For example, a 55-year-old postmenopausal woman with a T2N0 tumor and an RS of 18 falls squarely into this category, meaning chemotherapy is routinely omitted.
• Score 26–30: This is a range where doctors may consider chemotherapy based on other factors like tumor size or grade ^[5].
• Score 31–100: Chemotherapy is generally recommended because it has been shown to substantially reduce the risk of recurrence ^[6][5].

For Women Age 50 and Younger (Premenopausal)

The rules are more cautious for younger women because their cancers can behave differently ^[3].

• Node-Negative (Score 0–15): Chemotherapy provides little to no expected benefit ^[7].
• Node-Negative (Score 16–25): This is a critical range for younger women. Research suggests there may be a modest average benefit (around 2–5%) from adding chemotherapy ^[3][8]. Some experts believe this benefit might actually come from the chemotherapy “shutting down” the ovaries (inducing menopause), rather than the drugs killing cancer cells directly, but this is still being studied ^[9].
• Score 26+: Chemotherapy is typically recommended ^[5].
• 1 to 3 Positive Nodes: Current guidelines suggest that premenopausal women with 1 to 3 positive nodes generally should not use a low genomic score alone to omit chemotherapy, as RxPONDER showed they still derive benefit ^[4][2].

MammaPrint: When Clinical Risk Conflicts

MammaPrint is another common test that looks at 70 different genes. Unlike Oncotype’s 0–100 scale, MammaPrint gives a simpler result: Low Risk or High Risk ^[10].

Doctors often use MammaPrint when there is a “disagreement” between how the cancer looks (clinical risk) and how it behaves (genomic risk). For example, if you have a large tumor (clinically high risk) but the MammaPrint comes back “Low Risk,” the MINDACT trial supports shared decision-making, showing you might safely consider skipping chemotherapy ^[10][11]. However, this leaves a small residual risk, and premenopausal women with positive lymph nodes are still generally advised to consider chemotherapy ^[2][10].

Other Genomic Tests

While Oncotype and MammaPrint are the most frequent, your doctor might use others:

• Prosigna (PAM50): Often used to determine the “intrinsic subtype” and to predict the long-term risk of the cancer returning ^[1][12].
• EndoPredict: Combines genomic data with tumor size and node status to estimate long-term recurrence risk ^[13][14].
• Breast Cancer Index (BCI): This test is validated to help predict whether extending hormone therapy (to 7 or 10 years) will provide a specific benefit for you ^[15]. However, a “Low Benefit” result does not by itself make stopping automatically safe, as decisions must integrate your clinical risk and quality of life.

Why Genomic Testing Matters

Genomic testing has revolutionized ER-positive breast cancer care by allowing thousands of patients to safely avoid the toxicity of chemotherapy ^[3]. However, it is not a “crystal ball.” These scores must be interpreted alongside your pathology report and your personal health history. If your score falls into a “gray area,” it becomes a tool for a shared decision-making conversation with your oncologist about your personal goals and risk tolerance ^[16].